Nasdaq listed Hologic to acquire Endomag

Cambridge-headquartered Endomag is set to be acquired by Nasdaq listed Hologic Inc, in a deal worth almost £250m.

Hologic, a global leader in women's health, has signed an agreement to buy Endomagnetics Ltd, the pioneering scale up redefining breast cancer surgery. 

Endomag develops and sells breast surgery localisation and lymphatic tracing technologies. Its products include the Magseed® marker for magnetic tissue localization before surgery, the Magtrace® lymphatic tracing injectable for breast cancer staging and the Sentimag® platform, which supports both localization and lymphatic tracing.

Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment.

Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data framework for improving women’s well-being.

Endomag's CEO Eric Mayes said: “We are delighted to attract the strength and focus of Hologic to power the next phase of our growth. Our team is encouraged by our cultural alignment and the potential to strengthen a broader portfolio of solutions to improve women’s health globally.”